Evidence map›Paper›PMID 39198903›Full record

ArticleJournal of translational medicine2024

Engineered sensor actuator modulator as aqueous humor outflow actuator for gene therapy of primary open-angle glaucoma.

Samarendra Mohanty, Subrata Batabyal, Chinenye Idigo, Darryl Narcisse, Sanghoon Kim, Houssam Al-Saad, Michael Carlson, Kissaou Tchedre, Adnan Dibas

Abstract read
In one paragraph

Article in Journal of translational medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Samarendra MohantyNanoscope Technologies, LLC, 1312 Brown Trail, Bedford, TX, 76022, USA. smohanty@nanoscopetech.com.ORCID 0000-0002-6533-383X
Subrata BatabyalNanoscope Technologies, LLC, 1312 Brown Trail, Bedford, TX, 76022, USA.
Chinenye IdigoNanoscope Technologies, LLC, 1312 Brown Trail, Bedford, TX, 76022, USA.
Darryl NarcisseNanoscope Technologies, LLC, 1312 Brown Trail, Bedford, TX, 76022, USA.
Sanghoon KimNanoscope Technologies, LLC, 1312 Brown Trail, Bedford, TX, 76022, USA.
Houssam Al-SaadNanoscope Technologies, LLC, 1312 Brown Trail, Bedford, TX, 76022, USA.
Michael CarlsonNanoscope Technologies, LLC, 1312 Brown Trail, Bedford, TX, 76022, USA.
Kissaou TchedreNanoscope Technologies, LLC, 1312 Brown Trail, Bedford, TX, 76022, USA.
Adnan DibasNanoscope Technologies, LLC, 1312 Brown Trail, Bedford, TX, 76022, USA.

Funding

Sonogenetic Restoration of Vision for Retinitis PigmentosaU01EY035026 · NEI · NANOSCOPE TECHNOLOGIES, LLC · PI Samarendra Kumar Mohanty, Qifa Zhou · 2024 to 2026
$2.4M
Mechanosensitive Channel based Pressure-Modulating Gene Therapy for Glaucoma TreatmentR44EY033626 · NEI · NANOSCOPE TECHNOLOGIES, LLC · PI DIBAS, ADNAN ISMAIL, MOHANTY, SAMARENDRA KUMAR · 2022 to 2023
$1.6M
NEI NIH HHS R44 EY033626NEI NIH HHS U01 EY035026
6 · The paper itself

Abstract

Glaucoma, a blinding eye disease with optic neuropathy, is usually associated with elevated intraocular pressure (IOP). The currently available pharmacological and surgical treatments for glaucoma have significant limitations and side effects, which include systemic reactions to medications, patient non-compliance, eye infections, surgical device failure, and damage to the eye. Here, we present Sensor-Actuator-Modulator (SAM), an engineered double mutant version of the bacterial stretch-activated mechanosensitive channel of large conductance (MscL) that directly senses tension in the membrane lipid bilayer of cells and in response, transiently opens its large nonspecific pore to release cytoplasmic fluid. The heterologously expressed mechanosensitive SAM channel acts as a tension-activated pressure release valve in trabeculocytes. In the trabecular meshwork (TM), SAM is activated by membrane stretch caused by elevated IOP. We have identified several SAM variants that are activated at physiologically relevant pressures. Using this barogenetic technology, we have demonstrated that SAM is functional in cultured TM cells, and successfully transduced in vivo in TM cells by use of AAV2/8. Further, it is effective in enhancing aqueous humor outflow facility leading to lowering the IOP in a mouse model of ocular hypertension.

Indexed as

Aqueous HumorGenetic TherapyGlaucoma, Open-AngleAnimalsHumansIntraocular PressureMiceTrabecular MeshworkBarogeneticsGene therapyGlaucomaIntraocular pressurePressure regulator

Identifiers

PMID39198903
PMCPMC11350963

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.